Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01824290 · ClinicalTrials.gov registry record · Phase 3
A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 35
- Enrollment target
NCT01824290 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 35 participants.
The verdict
NCT01824290, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 35 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and efficacy of tadalafil in pediatric participants with pulmonary arterial hypertension. Participants will receive study treatment for 6 months in the double-blind period (Period 1), and then will be eligible to enroll into an open-label 2 year extension period (Period 2) during which participants will receive tadalafil.
Interventions
- DRUG Placebo
- DRUG Tadalafil
- DRUG ERA as specific PAH treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2014-02-05 |
| Est. Completion | 2021-03-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01824290
The ClinicalTrials.gov registry entry for NCT01824290 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01824290 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01824290 about?
NCT01824290 is a clinical study titled "A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)". The main purpose of this study is to evaluate the safety and efficacy of tadalafil in pediatric participants with pulmonary arterial hypertension. Participants will receive study treatment for 6 months in the double-blind period (Period 1), and then will be eligible to enroll into an open-label 2 ye...
What is the current status of trial NCT01824290?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 35 participants. The study started on 2014-02-05. Estimated completion is 2021-03-10.
What interventions are being tested in trial NCT01824290?
The interventions under investigation include: Placebo (DRUG), Tadalafil (DRUG), ERA as specific PAH treatment (DRUG).
Who is sponsoring clinical trial NCT01824290?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.